Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지

High-Dose-Rate Brachytherapy for Uterine Cervical Cancer : The Results of Different Fractionation Regimen

자궁경부암의 고선량률 근접치료 : 분할선량에 따른 결과 비교

  • Yoon, Won-Sup (Department of Radiation Oncology, College of Medicine, Korea University) ;
  • Kim, Tae-Hyun (Department of Radiation Oncology, College of Medicine, Korea University) ;
  • Yang, Dae-Sik (Department of Radiation Oncology, College of Medicine, Korea University) ;
  • Choi, Myung-Sun (Department of Radiation Oncology, College of Medicine, Korea University) ;
  • Kim, Chul-Yong (Department of Radiation Oncology, College of Medicine, Korea University)
  • 윤원섭 (고려대학교 의과대학 방사선종양학교실) ;
  • 김태현 (고려대학교 의과대학 방사선종양학교실) ;
  • 양대식 (고려대학교 의과대학 방사선종양학교실) ;
  • 최명선 (고려대학교 의과대학 방사선종양학교실) ;
  • 김철용 (고려대학교 의과대학 방사선종양학교실)
  • Published : 2002.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Although high-dose-rate (HDR) brachytherapy regimens have been practiced with a variety of modalities and various degrees of success, few studies on the subject have been conducted. The purpose of this study was to compare the results of local control and late complication rate according to different HDR brachytherapy fractionation regimens in uterine cervical cancer patients. Methods and Materials : From November 1992 to March 1998, 224 patients with uterine conical cancer were treated with external beam irradiation and HDR brachytherapy. In external pelvic radiation therapy, the radiation dose was $45\~54\;Gy$ (median dose 54 Gy) with daily fraction size 1.8 Gy, five times per week. In HDR brachytherapy, 122 patients (Group A) were treated with three times weekly with 3 Gy to line-A (isodose line of 2 cm radius from source) and 102 patients (Group B) underwent the HDR brachytherapy twice weekly with 4 or 4.5 Gy to line-A after external beam irradiation. Iridium-192 was used as the source of HDR brachytherapy. Late complication was assessed from grade 1 to 5 using the RTOG morbidity grading system. Results : The local control rate (LCR) at 5 years was $80\%$ in group A and $84\%$ in group B (p=0.4523). In the patients treated with radiation therapy alone, LCR at 5 years was $60.9\%$ in group A and $76.9\%$ in group B (p=0.2557). In post-operative radiation therapy patients, LCR at 5 years was $92.6\%$ In group A and $91.6\%$ in group B (p=0.8867). The incidence of late complication was $18\%$ (22 patients) and $29.4\%$ (30 patients), of bladder complication was $9.8\%$ (12 patients) and $14.7\%$ (15 patients), and of rectal complication was $9.8\%$ (12 patients) and $21.6\%$ (22 patients), in group A and B, respectively. Lower fraction sized HDR brachytherapy was associated with decrease in late complication (p=0.0405) (rectal complication, p=0.0147; bladder complication, p=0.115). The same result was observed in postoperative radiation therapy patients (p=0.0860) and radiation only treated patients (0=0.0370). Conclusion : For radiation only treated patients, a greater number of itemized studies on the proper fraction size of HDR brachytherapy, with consideration for stages and prognostic factors, are required. In postoperative radiation therapy, the fraction size of HDR brachytherapy did not have much effect on local control, yet the incidence of late complication increased with the elevation in fraction size. We suggest that HDR brachytherapy three times weekly with 3 Gy could be an alternative method of therapy.

목적 : 자궁경부암의 고선량률 근접치료는 각 기관마다 분할선량이 매우 다양하게 사용되고 있고 각 분할선량에 따른 치료 결과가 임상적으로 비교된 적이 적었던 바 저자들은 자궁경부암 환자에서 고선량률 근접치료의 분할선량에 따른 국소제어율과 합병증 발생을 비교하여 적정한 분할선량에 대해 알아보고자 하였다. 대상 및 방법 : 1992년 11월부터 1998년 3월까지 자궁경부암으로 진단 후 방사선치료를 시행한 224명을 대상으로 하였다. A군은 122명(수술 후 방사선치료 67명, 근치적 방사선치료 55명)으로 외부방사선 치료 후 고선량률 근접치료의 분할선량을 line-A (선원으로부터 반경 2 cm를 이은 등량선)에 3 Gy를 주당 3회씩 $6\~10$회 조사한 군이었고 B군는 102명(수술 후 방사선치료 49명, 근치적 방사선치료 53명)으로 외부방사선 치료가 시행된 후 분할선량을 line-A에 4 또는 4.5 Gy를 주당 2회씩 $6\~8$회 조사한 군이었다. 외부방사선치료는 10 MV X-선을 이용하여 전골반부에 $45\~54\;Gy$ (중앙값 54 Gy)를 조사하였다. 고선량률 근접치료는 이리디움(iridium)-192를 사용하였다. 합병증은 RTOG morbidity grading system에 따라 grade 1에서 5까지 나누어서 평가하였다. 결과 : A군과 B군의 5년 국소제어율은 각각 $80\%,\;84\%$였고(p=0.4523) B군에서 더 높은 국소제어율을 보였다. 근치적 방사선치료군에서는 A군과 B군의 5년 국소제어율이 각각 $62.9\%,\;76.9\%$ (p=0.2557), 수술 후 방사선치료군에서는 A군과 B군의 5년 국소제어율이 각각 $91.7\%,\;91.6\%$ (p=0.8867)였다. A군에서는 22명$(18.0\%)$에서 합병증이 발생하였고 B군에서는 30명$(29.4\%)$에서 합병증이 발생하였다. 방광에 대한 합병증은 A군에서 12명$(9.8\%)$이 발생하였고 grade 3 이상이 2명이었다. B군에서는 15명$(14.7\%)$에서 합병증이 발생하였으며 grade 3이상이 3명이었다. 직장에 대한 합병증은 A군에서 12명$(9.8\%)$에서 발생하였고 grade 3 이상이 1명이었고 B군에서는 22명$(21.6\%)$에서 발생하였고 grade 3 이상이 10명이었다. 합병증에 대한 단일변량분석에서 고선량률 근접치료의 분할 선량이 작으면 전체 합병증(0=0.0405), 직장의 합병증(0=0.0147), 방광의 합병증(0=0.115)이 감소하였고 수술 후 방사선치료군(p=0.0860) 및 근치적방사선치료군(0=0.0370)에서도 분할선량이 작으면 합병증은 감소하였다. 결론 : 근치적 방사선치료 시 고선량률 근접치료의 적절한 분할선량에 대한 평가는 환자의 병기, 예후인자 등을 고려한 다양한 분할선량에 대한 세분화한 연구가 더 필요할 것이다. 수술 후 방사선치료 시 고선량률 근접치료의 분할선량은 국소제어에 영향을 미치지 않았고 합병증에 대해선 분할선량이 커지면 다소 증가하는 면을 보여 분할선량을 3 Gy로 주 3회 시행하는 것이 하나의 치료 방법이 될 수 있을 것이다.

Keywords

References

  1. HiIaris BS. Evolution and general principIes of high dose rate brachytherapy. In : Nag eds. High Dose Rate Brachything Co. 1994:3-10
  2. Fu KK, PhiIIips TL. High-dose-rate versus low-dose-rate intracavitary brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1990;19:791-796 https://doi.org/10.1016/0360-3016(90)90511-H
  3. Teruki T, Toshihiko I, Hiroshi I, et aI. High-dose rate and low-dose-rate intracavitary therapy for carcinoma of the uterine cervix. Cancer 1993;72:2409-2414 https://doi.org/10.1002/1097-0142(19931015)72:8<2409::AID-CNCR2820720819>3.0.CO;2-N
  4. PateI FD, Sharma SC, Negi PS, GhosgaI S, Gupta BD. Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix : A cIinical trial. Int J Radiat Oncol Biol Phys 1993;28:335-341
  5. PiIepich MV, KraII J, George FW, et aI. Treatment-related morbidity in phase lll RTOG studies of extended-field irradiation for carcinoma of the prostate. J Radiat Oncol Biol Phys 1984;10:1861-1867 https://doi.org/10.1016/0360-3016(84)90263-3
  6. Petereit DG, Pearcey R. Literature analysis of high dose rate brachytherapy fractionation schedules in the treatment of cervical cancer : Is there an optimal fractionation schedule? Int J Radiat Oncol Biol Phys 1999;43:359-366 https://doi.org/10.1016/S0360-3016(98)00387-3
  7. SJ Huh. Current status of high dose rate brachytherapy in cervical cancer in Korea and optimal treatment schedule. J Korean Soc Ther Radiol Oncol 1998:16(4):357-366
  8. Kapp SK, StueckIschweiger GH, Kapp DS, Poschauko J, PickeI H, HackI A. Carcinoma of the cervix : analysis of complications after primary external beam radiation and Ir-192 HDR brachytherapy. Radiaother Oncol 1997;42:143-153 https://doi.org/10.1016/S0167-8140(96)01881-6
  9. Roman TN, Souhami L, Freeman CR, et aI. High dose rate afterloading intracavitary therapy in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1991;20:921-926 https://doi.org/10.1016/0360-3016(91)90186-8
  10. Wang GJ, Leung SW, Chen HC, et aI. High-dose-rate intracavitary brachytherapy (HDR-IC) in treatment of cervical carcinoma : 5-year results and implication of increased lowgrade rectal complication on initiation of an HDR-IC fractionation scheme. Int J Radiat Oncol Biol Phys 1997;38:391-398 https://doi.org/10.1016/S0360-3016(96)00624-4
  11. Chen SW, Liang JA, Yang SN, Liu RT, Lin FJ. The Prediction of late rectal complications following the treatment of uterine cervical cancer by high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2000;47:955-961 https://doi.org/10.1016/S0360-3016(00)00559-9
  12. Ichiro O, Tatsuo K, Naoyuki O, et aI. Late rectal compIication following high dose rate intracavitary brachytherapy in cancer of the cervix. Int J Radiat Oncol Biol Phys 1995;31:725-734 https://doi.org/10.1016/0360-3016(94)00547-8
  13. SeIke P, Roman TN, Souhami L, et aI. Treatment results of high dose rate brachytherapy in patients with carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1993;27:803-809 https://doi.org/10.1016/0360-3016(93)90452-2
  14. Souhami L, Seymour R, Roman TN. Weekly cisplatin pIus externao beam radiotherapy and high dose rate brachytherapy in patients with locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1993;27:871-878 https://doi.org/10.1016/0360-3016(93)90462-5
  15. Ferrigno R, Eduard F, Cassio A, et aI. High dose rate brachytherapy in the treatment of uterine cervix cancer. Analysis of dose effectiveness and late complications. Int J Radiat Oncol Biol Phys 2001;50:1123-1135 https://doi.org/10.1016/S0360-3016(01)01533-4
  16. Chatani M, Matayoshi Y, Masaki N, Teshima T, Inoue T. A prospective randomized study concerning the point dose in high-dose-rate intracavitary therapy for carcinoma of the uterine cervix. The final results. Strahlenther Onkol 1994;170(11):636-642
  17. Le Pechoux C, Yasuyuki A, Minako S, et aI. High dose rate brachytherapy for carcinoma of the uterine cervix : Comparison of two different fractionation regimen. Int J Radiat Oncol Biol Phys 1995;31:735-741 https://doi.org/10.1016/0360-3016(94)00573-7
  18. Yukihiro H, Minoru U, Ichiro N, et aI. Carcinoma of the uterine cervix : Twice-versus once-weekly high-dose-rate brachytherapy. Radiology 2001;219:207-212